Qiagen N.V.
NYSE:QGENMedical - Diagnostics & Research
-$0.35 today
- Market cap
- $10.23B
- Beta
- 0.66
- P/E (TTM)
- 18.6
- EPS (TTM)
- $1.94
- Dividend yield
- 0.69%
Volume 4.26M
Average 2.07M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Qiagen N.V.
NYSE:QGEN
Intrinsic Alpha fair value
Locked
Current Price
$49.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -0.2% | +10.1% (5yr)1 analysts |
| Revenue | N/A | N/A | -0.8% | +4.2% (5yr)6 analysts |
| Net Income | N/A | N/A | +0.1% | +10.0% (5yr)6 analysts |
| EBIT | N/A | N/A | -0.7% | +11.6% (5yr)6 analysts |
Analysis
Recent growth has been strongest in Net Income at +0.1% over three years. Forward estimates point to EBIT at +11.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Thermo Fisher Scientific Inc. NYSE:TMO | $259.44B | $700.22 | Fairly Valued | 25.3 | +21.06% |
Danaher Corporation NYSE:DHR | $163.94B | $233.02 | Overvalued | 34.0 | +3.06% |
Agilent Technologies, Inc. NYSE:A | $49.05B | $173.96 | Overvalued | 25.5 | +23.30% |
Revvity, Inc. NYSE:RVTY | $17.24B | $154.39 | Undervalued | 45.4 | +65.47% |
Bio-Techne Corporation NASDAQ:TECH | $11.44B | $72.80 | Overvalued | 78.3 | +26.24% |
Repligen Corporation NASDAQ:RGEN | $10.73B | $167.79 | Overvalued | 142.4 | +11.34% |
Bio-Rad Laboratories, Inc. NYSE:BIO | $9.85B | $366.36 | Fairly Valued | 45.4 | +21.45% |
Bruker Corporation NASDAQ:BRKR | $9.41B | $61.59 | Overvalued | -718.1 | +46.16% |
10x Genomics, Inc. NASDAQ:TXG | $7.07B | $58.19 | Overvalued | -196.0 | +264.66% |
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI | $1.13B | $7.54 | Not rated | -7.1 | +110.86% |
Continue the stock analysis
Jump to another research area for this company.